Literature DB >> 8873217

Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders.

D E Comings1, R Gade, D Muhleman, C Chiu, S Wu, M To, M Spence, G Dietz, E Winn-Deen, R J Rosenthal, H R Lesieur, L Rugle, J Sverd, L Ferry, J P Johnson, J P MacMurray.   

Abstract

Defects in serotonin metabolism, and abnormalities in both blood serotonin and tryptophan levels, have been reported in many psychiatric disorders. Tryptophan 2,3-dioxygenase (TDO2) is the rate limiting enzyme for the breakdown of tryptophan to N-formyl kenurenine. Functional variants of this gene could account for the observed simultaneous increases or decreases of both serotonin and tryptophan in various disorders. We have identified four different polymorphisms of the human TDO2 gene. Association studies show a significant association of one or more of these polymorphisms and Tourette syndrome (TS), attention deficit hyperactivity disorder (ADHD) and drug dependence. The intron 6G-->T variant was significantly associated with platelet serotonin levels. Only the association with TS was significant with a Bonferroni correction (p = 0.005). Our purpose here is not to claim these associations are proven, but rather to report preliminary results and show that easily testable polymorphisms are available. We hope to encourage additional research into the potential role the TDO2 gene in these and other psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873217     DOI: 10.1097/00008571-199608000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  10 in total

1.  Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene.

Authors:  Elena V Antontseva; Marina Yu Matveeva; Natalia P Bondar; Elena V Kashina; Elena Yu Leberfarb; Leonid O Bryzgalov; Polina A Gervas; Anastasia A Ponomareva; Nadezhda V Cherdyntseva; Yury L Orlov; Tatiana I Merkulova
Journal:  J Biosci       Date:  2015-12       Impact factor: 1.826

2.  Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Rajendra D Badgaiyan; Tomas Palomo; Mark S Gold
Journal:  Med Hypotheses       Date:  2014-02-26       Impact factor: 1.538

3.  Genetic aspects of childhood behavioral disorders.

Authors:  D E Comings
Journal:  Child Psychiatry Hum Dev       Date:  1997

Review 4.  Targeting TDO in cancer immunotherapy.

Authors:  Cheng-Peng Yu; Yun-Lei Song; Zheng-Ming Zhu; Bo Huang; Ying-Qun Xiao; Da-Ya Luo
Journal:  Med Oncol       Date:  2017-03-29       Impact factor: 3.064

5.  Two Genetic Mechanisms in Two Siblings with Intellectual Disability, Autism Spectrum Disorder, and Psychosis.

Authors:  Yu-Shu Huang; Ting-Hsuan Fang; Belle Kung; Chia-Hsiang Chen
Journal:  J Pers Med       Date:  2022-06-20

6.  Genetic polymorphisms affecting susceptibility to mercury neurotoxicity in children: summary findings from the Casa Pia Children's Amalgam clinical trial.

Authors:  James S Woods; Nicholas J Heyer; Joan E Russo; Michael D Martin; Federico M Farin
Journal:  Neurotoxicology       Date:  2014-08-07       Impact factor: 4.294

Review 7.  The genetics of Tourette syndrome: a review.

Authors:  Julia A O'Rourke; Jeremiah M Scharf; Dongmei Yu; David L Pauls
Journal:  J Psychosom Res       Date:  2009-09-30       Impact factor: 3.006

Review 8.  TDO as a therapeutic target in brain diseases.

Authors:  Cheng-Peng Yu; Ze-Zheng Pan; Da-Ya Luo
Journal:  Metab Brain Dis       Date:  2016-04-13       Impact factor: 3.584

9.  Detection of regulatory SNPs in human genome using ChIP-seq ENCODE data.

Authors:  Leonid O Bryzgalov; Elena V Antontseva; Marina Yu Matveeva; Alexander G Shilov; Elena V Kashina; Viatcheslav A Mordvinov; Tatyana I Merkulova
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

Review 10.  From Genetics to Epigenetics: New Perspectives in Tourette Syndrome Research.

Authors:  Luca Pagliaroli; Borbála Vető; Tamás Arányi; Csaba Barta
Journal:  Front Neurosci       Date:  2016-07-12       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.